Filing Flows › Comparisons › MDLN vs BSX
Medline vs Boston Scientific: MDLN and BSX compared
Medline is the larger company: $7.9B of revenue in its latest quarter (Q3 2026) against $5.1B for Boston Scientific (Q3 2026). Medline is growing faster (+10% against +1% a year earlier). Boston Scientific is more profitable, with an operating margin of 16.1% against 6.4%.
Where the money goes: MDLN and BSX
Medline (MDLN) · Q3 2026
Medline, Q3 2026: revenue $7.9B (+10% year over year), operating margin 6.4%, net earnings $198M, operating cash flow $1.0B. The chart follows the revenue to costs, profit and cash.
Boston Scientific (BSX) · Q3 2026
Boston Scientific, Q3 2026: revenue $5.1B (+1% year over year), operating margin 16.1%, net earnings $580M, operating cash flow $1.0B. The chart follows the revenue to costs, profit and cash.
| Medline (MDLN) | Boston Scientific (BSX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $7.9B | $5.1B |
| Revenue growth, Y/Y | +10% | +1% |
| Gross margin | 24.5% | 66.7% |
| Operating margin | 6.4% | 16.1% |
| Net earnings | $198M | $580M |
| Net margin | 2.5% | 11.3% |
| Operating cash flow | $1.0B | $1.0B |
| Free cash flow | $884M | $868M |
| Market value | $52.3B | $64.8B |
| P/E | 59.7× | 18.9× |
| Analysts’ mean target | $44.81 | $49.60 |
Where the revenue comes from
Boston Scientific
- Interventional Cardiology & Vascular Therapies: $1.3B (25%)
- Electrophysiology: $816M (16%)
- Endoscopy: $741M (14%)
- Urology: $661M (13%)
Questions
Which is bigger, Medline or Boston Scientific?
Medline is the larger company: $7.9B of revenue in its latest quarter (Q3 2026) against $5.1B for Boston Scientific (Q3 2026).
Is Medline or Boston Scientific growing faster?
Medline is growing faster (+10% against +1% a year earlier).
Which is more profitable, Medline or Boston Scientific?
Boston Scientific is more profitable, with an operating margin of 16.1% against 6.4%.
More: Medline earnings · how Medline makes money · Boston Scientific earnings · how Boston Scientific makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.